Literature DB >> 2813662

Adverse effects of clozapine.

R Grohmann1, E Rüther, N Sassim, L G Schmidt.   

Abstract

Adverse effects related to clozapine were assessed within a post-marketing drug surveillance program, the AMUP study, in two university psychiatric departments. In a randomly selected sample of patients (intensive drug monitoring) ADRs of any type were observed in 76% of clozapine-treated inpatients. Sedation, hypersalivation, increase in transaminases, and EEG changes were most frequently observed, but only rarely required changes in therapy. In 8.1% of 959 patients exposed to clozapine in the total inpatient population of the participating hospitals ADR led to withdrawal of clozapine; in 3.9% reactions judged as severe and potentially life-threatening occurred. Among these latter toxic delirium prevailed. In addition, four cases of severe cardiovascular and respiratory dysregulation were observed with the combination of clozapine and benzodiazepines. These cases and one case of sudden death under clozapine and haloperidol treatment are presented in some detail. The results obtained for clozapine are compared to data from this drug surveillance program for other neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2813662     DOI: 10.1007/bf00442571

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

1.  EPIDEMIOLOGICAL STUDIES OF ADVERSE DRUG REACTIONS.

Authors:  L G SEIDL; G F THORNTON; L E CLUFF
Journal:  Am J Public Health Nations Health       Date:  1965-08

2.  Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMUP program.

Authors:  R Grohmann; L G Schmidt; C Spiess-Kiefer; E Rüther
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Intensive hospital monitoring of adverse reactions to drugs.

Authors:  N Hurwitz; O L Wade
Journal:  Br Med J       Date:  1969-03-01

4.  Epidemiology of toxic delirium due to psychotropic drugs in psychiatric hospitals.

Authors:  L G Schmidt; R Grohmann; A Strauss; C Spiess-Kiefer; D Lindmeier; B Müller-Oerlinghausen
Journal:  Compr Psychiatry       Date:  1987 May-Jun       Impact factor: 3.735

5.  Assessment of adverse drug reactions in psychiatric hospitals.

Authors:  R Grohmann; H Hippius; B Müller-Oerlinghausen; E Rüther; J Scherer; L G Schmidt; A Strauss; B Wolf
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Adverse drug reactions. An epidemiological study at psychiatric hospitals.

Authors:  L G Schmidt; R Grohmann; H Helmchen; K Langscheid-Schmidt; B Müller-Oerlinghausen; W Poser; E Rüther; J Scherer; A Strauss; B Wolf
Journal:  Acta Psychiatr Scand       Date:  1984-07       Impact factor: 6.392

7.  [Drug monitoring in psychiatry (author's transl)].

Authors:  E Rüther; O Benkert; F Eckmann; I Eckmann; R Grohmann; H Helmchen; H Hippius; B Müller-Oerlinghausen; W Poser; L Schmidt; G Stille; A Strauss; K Uberla
Journal:  Arzneimittelforschung       Date:  1980

8.  Agranulocytosis during treatment with chlozapine.

Authors:  J Idänpään-Heikkilä; E Alhava; M Olkinuora; I P Palva
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

  8 in total
  18 in total

1.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 2.  Clarification of terminology in drug safety.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 4.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Tolerability of atypical antipsychotics.

Authors:  C Stanniland; D Taylor
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

Review 6.  Adverse effects of antipsychotic drugs.

Authors:  A K Malhotra; R E Litman; D Pickar
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

Review 7.  Clinically significant interactions of psychotropic agents with antipsychotic drugs.

Authors:  M C Meyer; R J Baldessarini; D C Goff; F Centorrino
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

8.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 9.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 10.  Adverse effects of antipsychotic agents. Do newer agents offer advantages?

Authors:  D G Owens
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.